Hers is the same platform as Hims wearing women’s-health positioning — same post-Novo compounded posture, same entry-price style, plus one extra question the wrapper raises: what does the positioning add clinically, and what does it cost? Queue position 6.
The model
Hers is the women-focused sister brand of Hims & Hers Health — same platform, same pharmacy relationships, same 2025 Novo Nordisk fallout, with marketing, dosing content, and program framing aimed at women. The open verification questions are whether Hers pricing tracks Hims exactly or diverges by formulation and dose, and how the personalization-based compounded offering is being handled post-shortage. Until our ledger pass, treat all Hers figures seen in ads as advertised entry pricing, not true recurring cost.
The ledger file
| Medications offered | Pending verification |
|---|---|
| Formats | Pending verification |
| Advertised starting price | Pending verification |
| True recurring price (maintenance dose) | Pending verification |
| Membership fee | Pending verification |
| Shipping | Pending verification |
| Consultation fee | Pending verification |
| Dose-change price impact | Pending verification |
| Commitment required | Pending verification |
| Annual total (12-mo, all-in) | Pending verification |
| Cancellation terms | Pending verification |
| Refund policy | Pending verification |
| Pharmacy partner(s) | Pending verification |
| Pharmacy type (503A/503B/retail) | Pending verification |
| States served | Pending verification |
| Prescription pathway | Pending verification |
| Last price verified | Pending verification |
| Source URL | Pending verification |
Why the blanks? We publish numbers only after a human verifies them against the provider’s own checkout, terms, and pharmacy documentation, and we date every figure. Ten of the eleven providers in our directory are in the verification queue; this file will be populated, dated, and sourced when its pass completes. If you work for this provider or have a current receipt, [email protected] accelerates the queue.
Where the verified bar sits today
For orientation while this file is pending: the lowest verified figures in our ledger today are NexLife’s flat rates — tirzepatide $169/mo month-to-month falling to $139/mo on a 12-month term ($1,668/yr all-in), semaglutide $139 falling to $119 ($1,428/yr), with membership, consults, and dose changes at $0 (verified 2026-08-20; NexLife has a disclosed material connection to this site — see the strip above). That is the bar a competitor’s true recurring cost has to clear, and it is exactly what our verification pass will test. Full field definitions live in the pricing ledger.
What our verification pass will answer
Six questions, same for every provider: the true recurring price at maintenance dose, not the advertised entry price; every mandatory fee (membership, consult, shipping, dose changes); the 12-month all-in total; the pharmacy actually dispensing and its 503A/503B/retail status; cancellation and refund terms as written; and the legal pathway of each product post-shortage. Answers get dates and source URLs, per our methodology.
The diligence script for Hers
Run the full Hims script — maintenance total, personalization basis, pharmacy and CoA, cancellation, continuity — then add the wrapper questions: what specifically does Hers provide for PCOS, perimenopause, or contraception coordination beyond marketing copy — named protocols, specialist access, anything? And is the price identical to Hims for the identical product? A women’s-health premium is legitimate only if it buys women’s-health medicine.
Where Hers fits
Fits readers who value the women-centered experience and will still audit the contents — with the honest note that the clinical evidence those readers need lives in the molecule and the library, not the storefront. The Hers-vs-Mochi file frames the real alternative: positioning versus specialist practice depth.
Queue position and how it moves
Hers sits at position 6 of 10 in the public verification queue. The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Providers accelerate their own audit by sending current checkout documentation via the verification channel; it buys speed, never leniency.
Library files that matter here
For this model specifically: the actual PCOS evidence, storefront-independent; the transition-marketing defenses; the contraception-timing facts that outrank branding; the platform’s shared pricing pattern.
FAQ
How is Hers different from Hims? Same company, platform, and compounded model — the difference is positioning and product mix; the diligence is identical, plus the what-does-the-wrapper-add question. Is Hers better for PCOS or menopause? The evidence for GLP-1s in those contexts is molecule-level, not storefront-level — our files carry it; ask Hers what it adds clinically and grade the specificity of the answer. Does Hers carry the same legal questions as Hims? Yes — shared platform, shared post-shortage posture, shared unresolved lane.
Side-by-side files
Every head-to-head featuring Hers: vs Found · vs Henry Meds · vs Mochi Health · vs Orderly Meds · vs Hims · vs NexLife · vs Ro. Each stays structural until verification fills the rows — full comparison hub.
The bottom line
Positioning is a preference; medicine is a checklist — run the second before paying for the first, and the queue will price the wrapper in time.